2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3260

Increased Frequency of Malignancies Synchronous to the Onset of Systemic Sclerosis in Anti-RNA Polymerase III Antibodies Positive Patients: A Eustar Multicentre Study
Abstract Number: 2798

Increased Frequency of the PTPN22W* Variant in Primary Sjögren’s Syndrome-Association with Low Type I IFN Scores in Peripheral Blood
Abstract Number: 3003

Increased Heparanase Expression in Keratinocytes Promotes Dermal Fibrosis in Scleroderma
Abstract Number: 1094

Increased IgA Plasmablasts Are Associated with Rheumatoid Arthritis-Related Autoantibodies in the Absence of Inflammatory Arthritis
Abstract Number: 55

Increased Incidence of Tuberculosis Among Systemic Lupus Erythematous Patients – Should Tuberculosis Screening at Diagnosis be the Next Step?
Abstract Number: 1850

Increased Levels of Immunoglobulin Binding Protein 1 Are Associated with Disease Activity Including Renal Damage in Patients with Systemic Lupus Erythematosus
Abstract Number: 3030

Increased Localization of Spleen Tyrosine Kinase (Syk) in Lipid Rafts of in Vitro TCR/CD3-CD28 Activated Lupus T Cells
Abstract Number: 2582

Increased Morbidity and Mortality in Female Versus Male Tumor Necrosis Factor-Transgenic Mice
Abstract Number: 40

Increased Mortality in Indigenous North Americans Persons with Rheumatoid Arthritis Is Partially Explained By Psychiatric and Physical Comorbidity: a Population Based Study
Abstract Number: 2471

Increased Muscle Interferon-Gamma Expression Levels in Juvenile Dermatomyositis
Abstract Number: 1737

Increased Osteoclast Precursors with an Elevated DC-STAMP Expression May Identify Psoriasis Patients at Risk for Psoriatic Arthritis
Abstract Number: 2822

Increased Peripheral Blood CCR6+/IL-23R+ Gamma Delta T Cells Are Associated with High Disease Activity in Patients with Axial Spondyloarthritis
Abstract Number: 3029

Increased Plasticity of Non-Classic Th1 Cells Towards the Th17 Phenotype
Abstract Number: 223

Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events
Abstract Number: 1511

Increased Prevalence of Anti-Nuclear and Anti-SSA Autoantibodies in African American Rheumatoid Arthritis Patients Versus Matched Caucasian Rheumatoid Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].